cerebrolysin 99% purity powder

Name:  Lynn
Wechat：  15914422644

Tel：+86  15914422644

Whatsapp: +852 6252 8290

Email：    guangsheng 5   @zgguangsheng.com

1. Core Molecular & Physicochemical Specifications

2. Mechanism of Action

1. Neurotrophic Signaling Activation: Peptides mimic BDNF/NGF, activating PI3K - Akt and MAPK - ERK pathways to promote neuronal survival, growth, and synaptic plasticity.
2. Neuroplasticity & Neurogenesis: Stimulates Shh pathway, enhances dendrite arborization, synaptogenesis, and neurogenesis in the hippocampus and cortex.
3. Neuroprotection: Reduces oxidative stress, inhibits pro - inflammatory cytokine release, and preserves blood - brain barrier integrity via tight junction upregulation.
4. Mitochondrial Function Preservation: Improves ATP production, reduces reactive oxygen species (ROS), and prevents neuronal apoptosis.
5. Cognitive Enhancement: Facilitates memory consolidation and information processing by boosting synaptic connectivity and neurotransmitter balance (acetylcholine, glutamate).

3. Biological Functions & Clinical Applications

3.1 Core Biological Effects

• Neuroregeneration: Accelerates neuronal repair and functional recovery after stroke, TBI, and spinal cord injuryCerebrolysin®.
• Cognitive Improvement: Enhances memory, learning, and attention in dementia and age - related cognitive decline.
• Neuroprotection: Shields neurons from ischemic, traumatic, and degenerative damage; slows neurodegenerative disease progression.
• Anti - Inflammatory: Mitigates neuroinflammation, reducing secondary brain injury post - trauma/ischemia.

3.2 Clinical Applications

4. Production & Quality Control

4.1 Manufacturing Process

1. Porcine Brain Protein Purification: Source from certified farms; extract and purify brain proteins to remove contaminants.
2. Enzymatic Hydrolysis: Controlled proteolysis produces low - MW peptides (<10 kDa) with neurotrophic activity.
3. Ultrafiltration & Lyophilization - Free Reconstitution: Ultrafiltration enriches active peptides; final formulation as sterile injectable solution.

4.2 Quality Testing Standards

5. Administration, Safety & Regulatory Status

5.1 Administration Routes & Dosage

5.2 Safety Profile

• Common Adverse Effects: Transient fever, headache, dizziness, injection - site pain (incidence <5%); mild and reversible.
• Rare Reactions: Allergic skin rash, hypotension (incidence <0.1%); no severe organ toxicity reported.
• Contraindications: Hypersensitivity to porcine products; epilepsy; severe renal impairment (CrCl <30 mL/min)Cerebrolysin®.
• Precautions: Use with caution in pregnancy/lactation (limited data); monitor renal function in long - term use.

5.3 Regulatory Status

• Approved in Russia, Eastern Europe, China, and other Asian countries for neurological disorders.
• Available by prescription only; included in multiple regional stroke/TBI guidelinesCerebrolysin®.
• Recognized as safe by the European Medicines Agency (EMA); not approved by the FDA for clinical use in the US.

6. Advantages of Cerebrolysin

1. Multimodal Neurotrophic Activity: Combines neuroprotection, neuroregeneration, and cognitive enhancement in one agent.
2. Clinical Guideline Endorsement: Evidence - based inclusion in stroke/TBI guidelines supports efficacyCerebrolysin®.
3. Favorable Safety: Low adverse effect rate enables long - term use in chronic neurological conditionsCerebrolysin®.
4. Flexible Administration: IV/IM routes suit acute/chronic treatment scenariosCerebrolysin®.